Alessio Amatu

Cytowane przez

	Wszystkie	Od 2019
Cytowania	8867	6351
h-indeks	39	34
i10-indeks	70	63

1400

700

350

1050

2011201220132014201520162017201820192020202120222023202433 39 71 157 309 442 587 741 932 1112 1310 1341 1208 438

Dostęp publiczny

Wyświetl wszystko

35 artykułów

4 artykuły

dostępne

niedostępne

Objęte finansowaniem

Współautorzy

Salvatore SienaUniversità degli Studi di Milano, Dipartimento di Oncologia, Ospedale Niguarda, Milano, ItalyZweryfikowany adres z unimi.it
Andrea Sartore-BianchiClinical Molecular Oncology, Niguarda Cancer Center, Milano - ItalyZweryfikowany adres z ospedaleniguarda.it
Silvia MarsoniIFOMZweryfikowany adres z ifom.eu
Federica Di NicolantonioUniversity of Torino, Dept of Oncology & Candiolo Cancer Institute, FPO - IRCCSZweryfikowany adres z unito.it
Gianluca MauriUniversità degli Studi di MilanoZweryfikowany adres z unimi.it
GIULIA SIRAVEGNAInstructor in Medicine, Harvard Medical SchoolZweryfikowany adres z mgh.harvard.edu
Andrea CassingenaATS Milano Città MetropolitanaZweryfikowany adres z ats-milano.it
Livio TrusolinoProfessor, University of Torino School of Medicine, ItalyZweryfikowany adres z ircc.it
Angelo VanzulliOspedale Niguarda, University of Milan, ItalyZweryfikowany adres z ospedaleniguarda.it
Filippo PietrantonioZweryfikowany adres z istitutotumori.mi.it
Giovanna MarrapeseNiguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, ItalyZweryfikowany adres z ospedaleniguarda.it
Sabrina ArenaIRCC-University of Torino Medical School Laboratory of Molecular Genetics S.P. 142, km 3.95 CandioloZweryfikowany adres z ircc.it
Fortunato CiardielloProfessore di oncologia medica, seconda università di napoliZweryfikowany adres z unina2.it
Giovanni Crisafulli, PhDBioinformatics Manager, Computational Scientist, IFOM, University of Turin,Zweryfikowany adres z ircc.it
Elio Gregory PizzutiloUniversità degli Studi di Milano, Niguarda Cancer Center, Grande Ospedale Metropolitano NiguardaZweryfikowany adres z ospedaleniguarda.it
Laura PalmeriNiguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, ItalyZweryfikowany adres z ospedaleniguarda.it
Silvia GhezziOspedale NiguardaZweryfikowany adres z ospedaleniguarda.it
Catia MoutinhoCEO at The Single-Cell WorldZweryfikowany adres z thesinglecellworld.com
Manel EstellerDirector, Josep Carreras Leukaemia Research Institute. University of Barcelona and ICREAZweryfikowany adres z carrerasresearch.org
Sandra MisaleAssistant Professor of Oncology, Johns Hopkins University School of MedicineZweryfikowany adres z mskcc.org

Obserwuj

Alessio Amatu

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy

Zweryfikowany adres z ospedaleniguarda.it

cancer - oncology - medical oncology - oncologia - oncologia medica


Tytuł Sortuj wg cytatów Sortuj wg roku Sortuj wg tytułu	Cytowane przez Cytowane przez	Rok
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015	1090	2015
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016	941	2016
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017	769	2017
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013	692	2013
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types A Amatu, A Sartore-Bianchi, S Siena ESMO open 1 (2), e000023, 2016	562	2016
Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019	335	2019
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014	289	2014
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ... Journal of the National Cancer Institute 109 (12), djx089, 2017	230	2017
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ... Gut 67 (11), 1995-2005, 2018	213	2018
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer A Amatu, A Sartore-Bianchi, K Bencardino, EG Pizzutilo, F Tosi, S Siena Annals of Oncology 30, viii5-viii15, 2019	210	2019
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ... Annals of oncology 26 (10), 2092-2097, 2015	195	2015
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ... Journal of the National Cancer Institute 108 (1), djv306, 2016	150	2016
Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ... Cancer Cell 34 (1), 148-162. e7, 2018	136	2018
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 … F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ... Cancer 122 (4), 574-581, 2016	135	2016
Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ... Clinical colorectal cancer 16 (3), e153-e163, 2017	132	2017
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019	131	2019
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomatà, V Fiano, ... Annals of oncology 26 (9), 1994-1999, 2015	129	2015
HER2 positivity predicts unresponsiveness to EGFR‐targeted treatment in metastatic colorectal cancer A Sartore‐Bianchi, A Amatu, L Porcu, S Ghezzi, S Lonardi, F Leone, ... The oncologist 24 (10), 1395-1402, 2019	122	2019
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ... Clinical cancer research 19 (8), 2265-2272, 2013	121	2013
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial A Sartore-Bianchi, S Lonardi, C Martino, E Fenocchio, F Tosi, S Ghezzi, ... ESMO open 5 (5), e000911, 2020	110	2020

Nie można teraz wykonać tej operacji. Spróbuj ponownie później.

Prace 1–20

Cytowania rocznie

Powielone cytowania

Scalone cytowania

Dodaj współautorówWspółautorzy

Obserwuj

Cytowane przez

Współautorzy